文献速递外周动脉疾病

全身免疫抑制不影响慢性肢体威胁性缺血患者的血运重建结局

Systemic immunosuppression does not affect revascularization outcomes in patients with chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2023-09-17

本研究纳入2005至2014年在本机构因慢性肢体威胁性缺血(CLTI)首次接受膝下旁路移植(BPG)或经皮腔内血管成形术伴或不伴支架置入(PTA/S)的1312例患者,比较全身免疫抑制与无免疫抑制者的结局。结果显示免疫抑制对BPG和PTA/S患者的围术期并发症、再干预、主要通畅率和截肢率均无显著影响,PTA/S组免疫抑制者截肢率单变量较高但多变量分析后无显著差异。

要点

  • BPG患者中免疫抑制与无免疫抑制的3年再干预率37% vs 33%(P=.75),无显著差异。
  • PTA/S患者免疫抑制者单变量主要截肢率23% vs 12%(P=.01),多变量校正后HR 1.46(95%CI 0.81-2.62;P=.20)。
  • 免疫抑制状态对BPG和PTA/S患者的围术期并发症均无显著影响(P>.05)。

核心结论

  • 与无免疫抑制者相比,慢性全身免疫抑制对下肢血运重建后的晚期结局(主要通畅率、再干预或主要截肢)无显著影响。

研究设计与样本

  • 回顾性识别2005年至2014年在本机构因CLTI首次接受膝下BPG或PTA/S的所有患者,共1312例。
  • 按手术类型和免疫抑制状态分层,免疫抑制定义为干预时正在进行的任何全身免疫抑制治疗持续≥6周。
  • 主要结局包括围术期并发症、再干预、主要通畅率和保肢,分别采用Kaplan-Meier和Cox比例风险模型进行单变量和多变量分析。

主要发现

  • 1312例患者中667例(51%)接受BPG,651例(49%)接受PTA/S,其中分别有65例(10%)和95例(15%)正在接受全身免疫抑制治疗。
  • 无论BPG还是PTA/S患者,围术期结局包括围术期死亡、心肌梗死、卒中、血肿或手术部位感染均无差异(P>.05)。
  • BPG患者中,免疫抑制与无免疫抑制的3年再干预率37% vs 33%(P=.75)、主要截肢率27% vs 15%(P=.64)、主要通畅率72% vs 66%(P=.35)均无显著差异。
  • PTA/S患者中,单变量分析显示再干预率37% vs 39%(P=.57)和主要通畅率59% vs 63%(P=.21)相似,但免疫抑制者主要截肢率较高(23% vs 12%;P=.01)。
  • 多变量Cox回归校正基线人口学、手术和解剖特征后,免疫抑制与再干预(HR 0.75;95%CI 0.49-1.16;P=.20)、主要截肢(HR 1.46;95%CI 0.81-2.62;P=.20)或主要通畅率(HR 0.84;95%CI 0.59-1.19;P=.32)均无显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Many patients with chronic limb-threatening ischemia (CLTI) have additional comorbidities requiring systemic immunosuppression. Few studies have analyzed whether these medications may inhibit graft integration and effectiveness, or conversely, whether they may prevent inflammation and/or restenosis. Therefore, our study aim was to examine the effect of systemic immunosuppression vs no immunosuppression on outcomes after any first-time lower extremity revascularization for CLTI. METHODS: We identified all patients undergoing first-time infrainguinal bypass graft (BPG) or percutaneous transluminal angioplasty with or without stenting (PTA/S) for CLTI at our institution between 2005 and 2014. Patients were stratified by procedure type and immunosuppression status, defined as ≥6 weeks of any systemic immunosuppression therapy ongoing at the time of intervention. Immunosuppression vs nonimmunosuppression were the primary comparison groups in our analyses. Primary outcomes included perioperative complications, reintervention, primary patency, and limb salvage, with Kaplan-Meier and Cox proportional hazard models used for univariate and multivariate analyses, respectively. RESULTS: Among 1312 patients, 667 (51%) underwent BPG and 651 (49%) underwent PTA/S, of whom 65 (10%) and 95 (15%) were on systemic immunosuppression therapy, respectively. Whether assessing BPG or PTA/S patients, there were no differences noted in perioperative outcomes, including perioperative mortality, myocardial infarction, stroke, hematoma, or surgical site infection (P > .05). For BPG patients, Kaplan-Meier analysis and log-rank testing demonstrated no significant difference in three-year reintervention (37% vs 33% [control]; P = .75), major amputation (27% vs 15%; P = .64), or primary patency (72% vs 66%; P = .35) rates. Multivariate analysis via Cox regression confirmed these findings (immunosuppression hazard ratio [HR] for reintervention, 0.95; 95% CI, 0.56-1.60; P = .85; for major amputation, HR, 1.44; 95% CI, 0.70-2.96; P = .32; and for primary patency. HR, 0.97; 95% CI, 0.69-1.38; P = .88). For PTA/S patients, univariate analysis revealed similar rates of reintervention (37% vs 39% [control]; P = .57) and primary patency (59% vs 63%; P = .21); however, immunosuppressed patients had higher rates of major amputation (23% vs 12%; P = .01). After using Cox regression to adjust for baseline demographics, as well as operative and anatomic characteristics, immunosuppression was not associated with any differences in reintervention (HR, 0.75; 95% CI, 0.49-1.16; P = .20), major amputation (HR, 1.46; 95% CI, 0.81-2.62; P = .20), or primary patency (HR, 0.84; 95% CI, 0.59-1.19; P = .32). Sensitivity analyses for the differences in makeup of immunosuppression regimens (steroids vs other classes) did not alter the interpretation of any findings in either BPG or PTA/S cohorts. CONCLUSIONS: Our findings demonstrate that patients with chronic systemic immunosuppression, as compared with those who are not immunosuppressed, does not have a significant effect on late outcomes after lower extremity revascularization, as measured by primary patency, reintervention, or major amputation.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Romary DJ, Darling JD, Patel PB, et al. Systemic immunosuppression does not affect revascularization outcomes in patients with chronic limb-threatening ischemia. J Vasc Surg. 2023. PMID: 37717639. doi:10.1016/j.jvs.2023.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。